Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
Alberto Blanco Sánchez(Hospital Universitario 12 De Octubre), Rosa Ayala(Hospital Universitario 12 De Octubre), Rodrigo Gil Manso(Hospital Universitario 12 De Octubre), Carmen Díaz Pedroche, D. Paredes(BioCruces Health research Institute), Jesús González Olmedo(Hospital Universitario 12 De Octubre), Gonzalo Carreño‐Tarragona, Joaquín Martínez‐López(Hospital Universitario 12 De Octubre)
Cited by 2
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523